Embed Doc
Copy Link
Readcast
Collections

CommentGo Back

Day 1Speaker’sBiographies

Join Plenary Session

MICHAEL ENTZEROTH

Chairman,

BioSingapore

Dr. Michael Entzeroth is the Senior Vice President, Drug Discovery atthe Experimental Therapeutic Centre, Biopolis, Singapore. He hasextensive experience in the pharmaceutical industry, with manysuccess records in drug discovery and development, as well as ingenerating entrepreneurial drug discovery cultures in an internationallycompetitive environment. He is presently Chairman of BioSingapore, anindustry association for life sciences businesses in Singapore.Dr. Michael Entzeroth is the founder of Pharma Resources Asia Pte Ltd,Singapore. Previously, he was Chief Scientific Officer of S*BIO Pte Ltd inSingapore and Vice President of CEREP SA in France where he was amember of the Executive Management Committee and responsible forthe company’s pharmacology service and discovery activities. From1985 to 1999, he was with Boehringer Ingelheim Germany, responsiblefor a variety of drug discovery programs and finally Head of High Throughput Screening.

TIM OLDHAM

President, Asia Pacific,

Hospira, Australia

Tim Oldham has been involved in the biogenerics industry for over fiveyears, first as a leader of Mayne Pharma's biogenerics program, then asa member and Chair of the joint development committee for MaynePharma's biogeneric collaboration with Pliva, and as a Chair of theBiosimilars and Biotechnology Committee of the European GenericMedicines Association.He recently returned to Australia as Hospira's President, Asia Pacific,and is looking to bring the company's global expertise in biogenerics tothe region. Tim holds PhD (Chemistry) and LLB degrees, and hasworked with McKinsey & Company, Mayne Pharma and Hospira inEurope, India and Asia.

SAMANATHA DU

Chief Scientific Officer and Executive Vice President,

Hutchison ChinaMediTech Ltd, China

and Managing Director,

HutchisonMediPharma Ltd

Dr. Du is the Managing Director of Hutchison Medipharma Limited;Chief Scientific Officer and Executive Vice President of Hutchison Chi-Med, a publicly traded company in London.Samantha joined Hutchison in 2001 and has since led all aspects of R&D and related investment activities in Hutchison. In 2003, shefounded Hutchison Medipharma Limited, a R&D based companyfocusing on oncology and autoimmune diseases, in Shanghai, China. The company has since grew to over 140 employees with cutting edgetechnology platforms and a rich portfolio of drug candidates at variousstages of development including one in US phase II trial for IBDdiseases and one in US phase I/II trials for radiosensitizer. Under Dr.Du’s leadership, Hutchison Medipharma has signed groundbreakingand landmark deals with global pharmaceutical companies in discoveryresearch collaboration with Eli Lilly in Indianapolis, US, Merck KGaA inDarmstadt, Germany, and P&G in Cincinnati, US. In 2006, the companyhas been rated as “the Pioneer in China, R&D” by Forbes China. Dr. Duplayed a key role in the successful IPO of Hutchison Chi-Med in Londonon May 19, 2006.Dr. Du received her Ph.D. in biochemistry from University of Cincinnati.Prior to Hutchison, she was at Pfizer’s global strategic operationdivision in US in charge of global Licensing and related MPA activitiesfor metabolic diseases. She started her research career at Pfizer’sGlobal R&D in Connecticut and led teams that delivered multiple INDsand NDAs in several therapeutic areas. Dr. Du served on FDA sponsoredworking committees while working at Pfizer and is currently an activeadviser on healthcare issues for various government agencies in China.

STEVEN FANG

Group CEO,

Cordlife Ltd, Singapore

Steven founded CordLife in Singapore, in 2001 and negotiated themerger with Cytomatrix leading to the establishment of CyGenics in2004. He led the team towards a successful listing of CyGenics on theAustralian Stock Exchange in June that year.